Alnylam Pharmaceuticals (ALNY) EPS (Diluted) Growth (3y) (2022 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) EPS (Diluted) Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.01% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.90% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 82.91% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 36.83% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -36.81% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.51% |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 46.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.39% |
| Mar 31, 2026 | 45.22% |
| Dec 31, 2025 | 35.46% |
| Sep 30, 2025 | 38.23% |
| Jun 30, 2025 | 37.77% |
| Mar 31, 2025 | 58.69% |
| Dec 31, 2024 | 33.00% |
| Sep 30, 2024 | 20.34% |
| Jun 30, 2024 | 56.41% |
| Mar 31, 2024 | 32.65% |
| Dec 31, 2023 | 19.53% |
| Sep 30, 2023 | 35.99% |
| Jun 30, 2023 | -12.39% |
| Mar 31, 2023 | 5.60% |
| Dec 31, 2022 | 12.30% |